JP2016518315A - ω３ペンタエン酸組成物および使用方法 - Google Patents

ω３ペンタエン酸組成物および使用方法 Download PDF

Info

Publication number
JP2016518315A
JP2016518315A JP2016500125A JP2016500125A JP2016518315A JP 2016518315 A JP2016518315 A JP 2016518315A JP 2016500125 A JP2016500125 A JP 2016500125A JP 2016500125 A JP2016500125 A JP 2016500125A JP 2016518315 A JP2016518315 A JP 2016518315A
Authority
JP
Japan
Prior art keywords
dpa
epa
dha
less
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016500125A
Other languages
English (en)
Japanese (ja)
Inventor
アブダル アジズ フォージー
アブダル アジズ フォージー
ジョージ ボボタス
ジョージ ボボタス
ロウロフ ロンゲン
ロウロフ ロンゲン
Original Assignee
マティナス バイオファーマ インコーポレイテッド
マティナス バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マティナス バイオファーマ インコーポレイテッド, マティナス バイオファーマ インコーポレイテッド filed Critical マティナス バイオファーマ インコーポレイテッド
Publication of JP2016518315A publication Critical patent/JP2016518315A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
JP2016500125A 2013-03-13 2013-12-17 ω３ペンタエン酸組成物および使用方法 Pending JP2016518315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
US61/780,948 2013-03-13
PCT/US2013/075661 WO2014143272A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Publications (1)

Publication Number Publication Date
JP2016518315A true JP2016518315A (ja) 2016-06-23

Family

ID=51537458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016500125A Pending JP2016518315A (ja) 2013-03-13 2013-12-17 ω３ペンタエン酸組成物および使用方法
JP2016501615A Pending JP2016512544A (ja) 2013-03-13 2014-03-12 ドコサペンタエン酸を含む組成物、および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016501615A Pending JP2016512544A (ja) 2013-03-13 2014-03-12 ドコサペンタエン酸を含む組成物、および使用方法

Country Status (4)

Country Link
EP (2) EP2968246A4 (fr)
JP (2) JP2016518315A (fr)
CA (2) CA2905671A1 (fr)
WO (4) WO2014143272A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6750831B2 (ja) * 2014-12-15 2020-09-02 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 非アルコール性脂肪性肝疾患の処置
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CA3023648C (fr) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Composition, et application et preparation pharmaceutique de cette derniere
CN108778284A (zh) * 2017-02-09 2018-11-09 S.L.A.制药股份公司 高纯度游离脂肪酸二十碳五烯酸减少溃疡性结肠炎患者粪便钙卫蛋白水平及预防临床复发
CN107006809B (zh) * 2017-04-11 2020-06-09 江南大学 一种有降血脂作用的醋洋葱制品及制备方法
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098311A1 (fr) * 2003-05-05 2004-11-18 Denofa As Huiles de poisson a profil d'acides gras modifie, leur procede de production et leurs utilisations
EP1656839A1 (fr) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition contenant un mélange de lipide
US7884131B2 (en) * 2004-11-19 2011-02-08 Martek Biosciences, Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP1714564A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia Méthode pour le traitement ou la prévention des insuffisances respiratoires
WO2007058523A1 (fr) * 2005-11-17 2007-05-24 N.V. Nutricia Composition comprenant de l'acide docosapentaenoique
KR100684642B1 (ko) * 2006-09-14 2007-02-22 주식회사 일신웰스 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법
BRPI1007518A2 (pt) * 2009-02-10 2018-02-20 Amarin Pharma, Inc. uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia
NZ595204A (en) * 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
EP2424521A4 (fr) * 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US8586567B2 (en) * 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
WO2013033618A1 (fr) * 2011-09-02 2013-03-07 Arctic Nutrition As Compositions lipidiques à forte teneur en dha
AU2013277441B2 (en) * 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Also Published As

Publication number Publication date
WO2014143275A1 (fr) 2014-09-18
CA2905795A1 (fr) 2014-10-09
EP2986148A2 (fr) 2016-02-24
EP2968246A1 (fr) 2016-01-20
WO2014143272A1 (fr) 2014-09-18
EP2968246A4 (fr) 2016-08-03
JP2016512544A (ja) 2016-04-28
CA2905671A1 (fr) 2014-09-18
WO2014158256A1 (fr) 2014-10-02
WO2014165190A2 (fr) 2014-10-09
WO2014165190A3 (fr) 2015-01-29

Similar Documents

Publication Publication Date Title
US20210205254A1 (en) Omega-3 pentaenoic acid compositions and methods of use
JP2016518315A (ja) ω３ペンタエン酸組成物および使用方法
JP2019172697A (ja) ω３ペンタエン酸組成物および使用方法
WO2014179341A1 (fr) Traitement par des compositions d'acide gras oméga-3
US20140194512A1 (en) Compositions comprising docosapentaenoic acid and methods of use
JP2016500055A (ja) トリグリセリドを低減させる方法